ArticleESMO open2026

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

L Paracchini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.